The Biomarkers Consortium’s Cancer, Inflammation and Immunity, Metabolic Disorders and Neuroscience Steering Committees are responsible for identifying and moving forward promising pre-competitive biomarkers projects for implementation by the Biomarkers Consortium, as well as overseeing each individual project under its purview. The members of each Steering Committee represent a variety of sectors, including academia, government, industry and not-for-profit/advocacy organizations, and are led by two co-chairs representing two of the following three sectors: academia, government or industry.
| Linda Brady, Ph.D., NIH/NIMH (Co-Chair)
Penny Dacks, Ph.D., Association for Frontotemporal Degeneration (Co-Chair) Danielle Graham, Ph.D., Biogen (Co-Chair) William Potter, M.D., Ph.D., (Co-Chair Emeritus) Marc Aafjes, M.B.A., Deliberate AI Alexandre Akoulitchev, Ph.D., Oxford Biodynamics Muneer Ali, M.D., Tempus Anthony Bannon, Ph.D., AbbVie Richard Batrla, M.D., Ph.D., SunBird Bio Anna Berdine, Alamar Bio Wade Berrettini, M.D., Ph.D., UPenn Diane Bovenkamp, Ph.D., BrightFocus Foundation Mark Brody, Ph.D., Evolution Research Group Xuemei Cai, M.D., Pfizer Maria Carrillo, Ph.D., Alzheimer’s Association® Emily Collins, Ph.D., Eli Lilly Nicole Davis, Ph.D., Ultragenyx Francesca DeSimone, Ph.D., Fujirebio US Ken Duckworth, M.D., National Alliance on Mental Illness John Dwyer, J.D., Global Alzheimer’s Platform Foundation Lorna Farrelly, Ph.D., Regeneron Thomas Finn, Ph.D., FDA/CBER Bernard Fischer, M.D., FDA/CDER Mariana Fontes, Ph.D., Olink Proteomics Tim Hammond, Ph.D., Sanofi Glenn A. Harris, Ph.D., Rainwater Charitable Foundation Robert Iannone, M.D., Jazz Pharmaceuticals Morten Karsdal, Ph.D., Nordic Bioscience Showkhin Khan, Ultragenyx Katherine Jung, Ph.D., NIH/NIAAA Hartmuth Kolb, Ph.D., Enigma Biomedical Group Walter Koroshetz, M.D., NIH/NINDS Walter Kostich, Ph.D., National MS Society, Inc. Frank Lebeda, Ph.D., US Military |
Tara Lincoln, MLIS, The Robert Packard Center for ALS Research at Johns Hopkins Andrew Lowe, MSD Miroslaw Mackiewicz, Ph.D., NIH/NIA David Millis, M.D., M.B.A., Ph.D., FDA/CDER Larry Mimms, Ph.D., Schizophrenia & Psychosis Action Alliance Satoshi Minoshima, M.D., Ph.D., Radiological Society of North America Laura Mitic, Ph.D., The Bluefield Project to Cure FTD Mike Montalto, Ph.D., Path AI Mario Morken, Sunbird Bio Andrea Mortera, Empatica Sze-Ling Ng, Ph.D., GSK Laura Nisenbaum, Ph.D., Alzheimer’s Drug Discovery Foundation Dimitry Ofengeim, Ph.D., Sanofi Lovingly Park, Ph.D., Alector Mary Ann Pelleymounter, Ph.D., NIH/NINDS Christos Petropoulos, Ph.D., LabCorp Brooke Rhead, Ph.D., Tempus Ziad Saad, Ph.D. , Johnson & Johnson Mert Sahin, Ph.D., Durin Technologies Steve Sands, Ph.D., Amgen Swati Sathe, M.D., CHDI Foundation Daniel Smith, Ph.D., Alkermes Gad Soffer, M.S., General Metabolics Joyce Suhy, Ph.D., Clario Aishu Sukumar, M.Phil., M.P.H., Gates Ventures Johannes Tauscher, M.D., Takeda Ina Tesseur, Ph.D., UCB Biopharma SPRL Chris Turck, Ph.D., Max Planck Institute of Psychiatry Eugeen Vanmechelen, Ph.D., ADx NeuroSciences Philip Verghese, Ph.D., C2N Diagnostics Shidong Wang, Standard BioTools Christopher Weber, Ph.D., Alzheimer’s Association® Joel Wommack , Ph.D., Standard Biotools Henrik Zetterberg, M.D., Ph.D., University of Gothenburg |